{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000048","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-06-16T20:34:58+00:00","discovered_at":"2026-06-16T20:36:00.292122+00:00","generated_at":"2026-06-16T20:37:12.376415+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Travere CRO William Rote to retire Feb 2027; CMO Inrig promoted to EVP, Head of R&D","bullets":["William Rote, Ph.D., Chief Research Officer, to retire effective Feb 17, 2027, after 10 years.","Jula Inrig, M.D., current Chief Medical Officer, will assume Rote's responsibilities.","Effective July 1, 2026, Dr. Inrig becomes EVP, Head of R&D and Chief Medical Officer.","Travere expects to enter into a consulting arrangement with Dr. Rote post-retirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000048","json":"https://secwatch.observer/filing/0001438533-26-000048.json","markdown":"https://secwatch.observer/filing/0001438533-26-000048.md","text":"https://secwatch.observer/filing/0001438533-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/tvtx-20260612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T20:37:12.376415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ed9086126","claim":"Jula Inrig was named as Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics, Inc..","evidence_excerpt":"Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Executive Vice President, Head of Research & Development and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"c77637f705","claim":"William Rote departed as Chief Research Officer at Travere Therapeutics, Inc..","evidence_excerpt":"On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Research Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}